His laboratory focuses on understanding prostate cancer disease progression. Most recently, his group has been trying to understand therapy resistance in the context of lineage plasticity, which implicates epigenetic as well as genomic alterations. “We are now, more than ever, poised to apply genomic and epigenetic discoveries into clinical practice”, he is convinced. “Using Precision Oncology approaches, we should improve management and outcome of men with aggressive prostate cancer.”
Besides research, Mark Rubin, who is US-born, is also passionate about sports and fully enjoys the outdoor life in Switzerland: biking in the mountains, swimming, cross-country skiing, and hiking. To break up the intellectual day, he also likes traveling and going to the movies with family.
In his lecture at the Collegium generale, Mark Rubin will present the next steps of the BCPM into the future, show its relevance for Switzerland, and illustrate why precision medicine is called the medicine of the future.
Lecture at the Collegium generale on Wednesday 25 September 2019:
"Bern Center for Precision Medicine: Die ersten Schritte in die Zukunft“
Prof. Dr. Mark Rubin, Bern Center for Precision Medicine (BCPM), Universität Bern